# Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects

> **NCT03383276** · PHASE1 · UNKNOWN · sponsor: **Beijing Tongren Hospital** · enrollment: 34 (estimated)

## Conditions studied

- Blepharokeratoconjunctivitis

## Interventions

- **DRUG:** IL-1Ra

## Key facts

- **NCT ID:** NCT03383276
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-18
- **Primary completion:** 2018-03-25
- **Final completion:** 2018-06-10
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2017-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03383276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03383276, "Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03383276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*